| Tobacco Cessation |
1 |
1 |
| Secondhand Tobacco Smoke |
0 |
0.73 |
| Tobacco Use |
0 |
0.67 |
| Cardiovascular Risk Management |
0 |
0.98 |
| Toxicology |
0 |
0.57 |
| Smoking |
0 |
0.56 |
| Coronary Artery Disease (CAD) |
0 |
0.44 |
| Heart |
0 |
0.39 |
| E-cigarettes |
0 |
0.99 |
| Cardiovascular disease |
0 |
0.17 |
| Lipids Management |
0 |
0.17 |
| Meta-Analysis |
0 |
0.17 |
| Oxidative Stress |
0 |
0.16 |
| Atherosclerosis |
0 |
0.11 |
| Cerebrovascular Accident |
0 |
0.11 |
| Healthcare and Medical Technology |
0 |
0.11 |
| Stress |
0 |
0.11 |
| Lung Cancer |
0 |
0.08 |
| ACE Inhibitor |
0 |
0.06 |
| Adolescent Medicine |
0 |
0.06 |
| Adverse Effects |
0 |
0.06 |
| Artificial Intelligence |
0 |
0.06 |
| Aspirin |
0 |
0.06 |
| Asthma |
0 |
0.06 |
| Biomarker |
0 |
0.06 |
| Cancer |
0 |
0.06 |
| Carcinogen |
0 |
0.06 |
| Child |
0 |
0.06 |
| Chronic Obstructive Pulmonary Disease |
0 |
0.06 |
| Circadian Rhythm |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Intensive Care Unit |
0 |
0.06 |
| Lung |
0 |
0.06 |
| Microbiome |
0 |
0.06 |
| Patient Safety |
0 |
0.06 |
| Statins |
0 |
0.06 |
| Transdermal |
0 |
0.06 |